Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The effect of maternal iron deficiency on zinc and copper levels and on genes of zinc and copper metabolism during pregnancy in the rat.

Cottin SC, Roussel G, Gambling L, Hayes HE, Currie VJ, McArdle HJ.

Br J Nutr. 2019 Jan;121(2):121-129. doi: 10.1017/S0007114518003069. Epub 2018 Nov 28.

PMID:
30482256
2.

Systematic physician cross-checking between emergency department physicians is associated with a significant reduction in adverse events.

Currie V, Hartshorn S.

Arch Dis Child Educ Pract Ed. 2019 Apr;104(2):111. doi: 10.1136/archdischild-2018-315850. Epub 2018 Aug 28. No abstract available.

PMID:
30154133
3.

Changes in glycaemic control, blood pressure and lipids 5 years following laparoscopic adjustable gastric banding combined with medical care in patients with type 2 diabetes: a longitudinal analysis.

Mistry P, Currie V, Super P, le Roux CW, Tahrani AA, Singhal R.

Clin Obes. 2018 Jun;8(3):151-158. doi: 10.1111/cob.12244. Epub 2018 Mar 4.

PMID:
29504275
4.

Porcine Small and Large Intestinal Microbiota Rapidly Hydrolyze the Masked Mycotoxin Deoxynivalenol-3-Glucoside and Release Deoxynivalenol in Spiked Batch Cultures In Vitro.

Gratz SW, Currie V, Richardson AJ, Duncan G, Holtrop G, Farquharson F, Louis P, Pinton P, Oswald IP.

Appl Environ Microbiol. 2018 Jan 2;84(2). pii: e02106-17. doi: 10.1128/AEM.02106-17. Print 2018 Jan 15.

5.

'Holes in the head': a case of enlarged parietal foramina.

Currie V, Mulik R.

Arch Dis Child. 2017 Nov;102(11):1070. doi: 10.1136/archdischild-2016-312303. Epub 2017 Feb 23. No abstract available.

PMID:
28232462
6.

Evaluation of the LiveWell@School Food Initiative Shows Increases in Scratch Cooking and Improvement in Nutritional Content.

Schober DJ, Carpenter L, Currie V, Yaroch AL.

J Sch Health. 2016 Aug;86(8):604-11. doi: 10.1111/josh.12413.

PMID:
27374350
7.

Clinical trials in New Zealand--an update.

Currie V, Jull A.

N Z Med J. 2012 Apr 20;125(1353):22-9.

PMID:
22522268
8.
9.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C.

J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733.

PMID:
18323546
10.

A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.

Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C.

J Am Geriatr Soc. 2006 Jul;54(7):1119-24.

PMID:
16866685
11.

Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.

Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C.

Breast Cancer Res Treat. 2006 Aug;98(3):343-8. Epub 2006 Mar 16.

PMID:
16541322
12.

Relationship between quality of care, staffing levels, skill mix and nurse autonomy: literature review.

Currie V, Harvey G, West E, McKenna H, Keeney S.

J Adv Nurs. 2005 Jul;51(1):73-82. Review.

PMID:
15941463
13.

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA.

Clin Breast Cancer. 2005 Apr;6(1):55-60.

PMID:
15899073
14.

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.

Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA.

Clin Cancer Res. 2004 Sep 1;10(17):5754-61.

15.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C.

Clin Cancer Res. 2001 Dec;7(12):3934-41.

16.

Social support, intrusive thoughts, and quality of life in breast cancer survivors.

Lewis JA, Manne SL, DuHamel KN, Vickburg SM, Bovbjerg DH, Currie V, Winkel G, Redd WH.

J Behav Med. 2001 Jun;24(3):231-45.

PMID:
11436544
17.

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA.

J Clin Oncol. 2001 May 15;19(10):2587-95.

PMID:
11352950
18.

Intrusive thoughts and psychological distress among breast cancer survivors: global meaning as a possible protective factor.

Vickberg SM, Bovbjerg DH, DuHamel KN, Currie V, Redd WH.

Behav Med. 2000 Winter;25(4):152-60.

PMID:
10789021
19.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L.

J Clin Oncol. 1999 Apr;17(4):1118.

PMID:
10561169
20.

Patients' pretreatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea.

Montgomery GH, Tomoyasu N, Bovbjerg DH, Andrykowski MA, Currie VE, Jacobsen PB, Redd WH.

Ann Behav Med. 1998 Spring;20(2):104-9.

PMID:
9989316
21.

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L.

J Clin Oncol. 1998 Oct;16(10):3353-61. Review. Erratum in: J Clin Oncol. 2006 May 10;24(14):2220. Albanel, J [corrected to Albanell, J ].

PMID:
9779712
22.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L.

Cancer Invest. 1998;16(2):67-71. No abstract available.

PMID:
9512671
23.

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L.

Eur J Cancer. 1997 Nov;33(13):2198-202.

PMID:
9470806
24.

Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.

Seidman AD, Hudis CA, McCaffrey J, Tong W, Currie V, Moynahan ME, Theodoulou M, Tepler I, Gollub M, Norton L.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-72-S17-76.

PMID:
9374099
25.

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L.

J Clin Oncol. 1996 Jun;14(6):1877-84.

PMID:
8656256
26.

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L.

Semin Oncol. 1996 Feb;23(1 Suppl 1):58-64.

PMID:
8629040
27.

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L.

J Clin Oncol. 1996 Jan;14(1):58-65.

PMID:
8558221
28.

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al.

Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.

PMID:
8643965
29.

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al.

J Clin Oncol. 1995 Oct;13(10):2575-81.

PMID:
7595709
30.

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al.

J Clin Oncol. 1995 May;13(5):1152-9.

PMID:
7537798
31.

Fatal neutropenia associated with long-term tamoxifen therapy.

Miké V, Currie VE, Gee TS.

Lancet. 1994 Aug 20;344(8921):541-2. No abstract available.

PMID:
7914632
32.

Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.

King SY, Agra AM, Shen HS, Chi CL, Adams DB, Currie VE, Bertino JR, Pieniaszek HJ Jr, Quon CY.

Cancer Chemother Pharmacol. 1994;35(2):101-8.

PMID:
7987984
33.

Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.

Reichman BS, Seidman AD, Crown JP, Heelan R, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, et al.

Ann N Y Acad Sci. 1993 Nov 30;698:398-402. No abstract available.

PMID:
7506506
34.

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, et al.

J Clin Oncol. 1993 Oct;11(10):1943-51.

PMID:
7691998
35.

Phase II trial of carboplatin and etoposide in metastatic breast cancer.

Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A, Currie V, Yao TJ, Hudis C, Seidman A, et al.

Cancer. 1993 Feb 15;71(4):1254-7.

PMID:
8435802
36.

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

Seidman AD, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, et al.

J Natl Cancer Inst Monogr. 1993;(15):171-5.

PMID:
7517153
37.

Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy.

Geller NL, Hakes TB, Petroni GR, Currie V, Kaufman R.

Cancer. 1990 Oct 15;66(8):1678-84.

PMID:
2208022
38.

The combined use of radiation therapy and lonidamine in the treatment of brain metastases.

DeAngelis LM, Currie VE, Kim JH, Krol G, O'Hehir MA, Farag FM, Young CW, Posner JB.

J Neurooncol. 1989 Sep;7(3):241-7.

PMID:
2677257
39.

Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer.

Andrykowski MA, Jacobsen PB, Marks E, Gorfinkle K, Hakes TB, Kaufman RJ, Currie VE, Holland JC, Redd WH.

Cancer. 1988 Dec 15;62(12):2607-13.

PMID:
3191461
40.

Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer.

Jacobsen PB, Andrykowski MA, Redd WH, Die-Trill M, Hakes TB, Kaufman RJ, Currie VE, Holland JC.

Cancer. 1988 Jan 15;61(2):379-85.

PMID:
3334973
41.

Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.

Casper ES, Raymond V, Hakes TB, Currie VE, Kaufman RJ.

Cancer Treat Rep. 1987 Dec;71(12):1289-90. No abstract available.

PMID:
3480045
42.

Phase II trial of 10-deaza-aminopterin in advanced breast cancer.

Thongprasert S, Currie VE, Budman D.

Cancer Treat Rep. 1987 Jan;71(1):95-6. No abstract available.

PMID:
3791275
43.

Initial clinical studies of piritrexim.

Laszlo J, Brenckman WD Jr, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C.

NCI Monogr. 1987;(5):121-5.

PMID:
3323908
44.

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, et al.

J Clin Oncol. 1985 Jun;3(6):818-26.

PMID:
3859587
45.

Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.

Young CW, Currie VE, Kim JH, O'Hehir MA, Farag FM, Kinahan JE.

Oncology. 1984;41 Suppl 1:60-5.

PMID:
6717897
46.

Phase II trial of 10-deaza-aminopterin in patients with advanced colorectal cancer.

Cheng EW, Currie VE, Yagoda A.

Am J Clin Oncol. 1983 Aug;6(4):469-71.

PMID:
6869317
47.

Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.

Sternberg CN, Magill GB, Sordillo PP, Cheng E, Currie VE.

Am J Clin Oncol. 1983 Aug;6(4):459-62.

PMID:
6688151
48.

Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients.

Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman RJ, Hakes TB, Currie VE.

Cancer. 1983 Mar 1;51(5):803-7.

PMID:
6687378
49.

Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.

Currie VE, Warrell RP Jr, Arlin Z, Tan C, Sirotnak FM, Greene G, Young CW.

Cancer Treat Rep. 1983 Feb;67(2):149-54.

PMID:
6825121
50.

A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP.

N Engl J Med. 1982 Jan 28;306(4):201-6.

PMID:
7033783

Supplemental Content

Loading ...
Support Center